Urology Consumables Articles & Analysis: Older

5 news found

FDA Approves Taiho’s LYTGOBI® (futibatinib) Tablets for Previously Treated, Unresectable, Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma

Taiho Pharmaceutical also has development programs in allergy and immunology, urology and consumer healthcare products. Our corporate philosophy is simple: “We strive to improve human health and contribute to a society enriched by ...

Sep. 30, 2022

ByTaiho Oncology, Inc.

$Drug Combination Meets Survival Endpoint in Phase III Pivotal Trial Involving Participants With Refractory Metastatic Colorectal Cancer$

Drug Combination Meets Survival Endpoint in Phase III Pivotal Trial Involving Participants With Refractory Metastatic Colorectal Cancer

Sep. 12, 2022

ByTaiho Oncology, Inc.

Cullinan Oncology and Taiho Pharmaceutical Announce Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 and Taiho’s Acquisition of Cullinan Pearl

May 12, 2022

ByTaiho Oncology, Inc.

U.S. Food and Drug Administration (FDA) Accepts for Priority Review Taiho Oncology’s New Drug Application for Futibatinib for Cholangiocarcinoma

Mar. 30, 2022

ByTaiho Oncology, Inc.

Taiho and Lung Therapeutics Enter Into an Exclusive License Agreement in Japan for LTI-01, Treatment for Loculated Pleural Effusions

Taiho Pharmaceutical also has development programs in allergy and immunology, urology, and consumer healthcare products. Our corporate philosophy is simple: “We strive to improve human health and contribute to a society enriched by ...

Nov. 12, 2020

ByLung Therapeutics, Inc.

Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you